Redefining Neuroimmune Therapeutics

At Ortega NeuroRx, we are advancing a new frontier in Alzheimer’s treatment through the development of targeted immunotherapies that disrupt disease at its upstream immune trigger. Unlike conventional approaches that focus on downstream amyloid or tau pathology, Ortega targets self-reactive CD8 T cells—key drivers of age-related neuroinflammation and neurodegeneration.

Our research has uncovered a unique population of CD8 memory T cells that accumulate with age, infiltrate the brain, and initiate neuronal damage long before cognitive symptoms emerge. Ortega’s platform is designed to block these cells across three critical mechanisms: presence in peripheral circulation, homing to the brain, and neurotoxic function at the site of inflammation. By intercepting this immune cascade, our therapies aim to halt disease progression before irreversible damage occurs.

To enable precision targeting, Ortega develops biologics guided by proprietary T cell–specific biomarkers and functional assays derived from human and preclinical models. This allows for patient stratification, early intervention, and monitoring of immune activity over time. Our approach also leverages scalable, modular delivery systems compatible with GMP standards and clinical translation.

By combining upstream intervention, precision immunology, and translational insight, Ortega NeuroRx is redefining how neurodegenerative diseases are treated—moving beyond symptomatic care toward disease interception. Our science offers a bold alternative to traditional paradigms, with the potential to transform outcomes for millions at risk of Alzheimer’s and other neuroimmune disorders.